Bimekizumab, a humanized monoclonal IgG1 antibody that neutralizes both IL-17A and IL-17F, has shown substantial efficacy in the treatment of psoriasis (PSO), psoriatic arthritis (PsA), and AxSpA. Here, IL17A is linked to psoriatic arthritis.